je.st
news
Tag: enrollment
Annual Enrollment Slideshow
2015-05-22 23:28:43| PortlandOnline
2015-16 Benefits Annual Enrollment .pdf PDF Document, 427kbCategory: Annual Enrollment Information
Tags: annual
slideshow
enrollment
Open Enrollment Meeting Schedule
2015-05-15 22:49:54| PortlandOnline
2015-16 Open Enrollment meeting schedule PDF Document, 67kbCategory: Annual Enrollment Information
Tags: open
meeting
schedule
enrollment
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
2015-05-07 18:57:31| Biotech - Topix.net
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that it has been notified by NINDS that the ongoing clinical trial of MN-166 in progressive multiple sclerosis is now fully enrolled. Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study.A Randomization is expected to be completed in approximately 4 - 6 weeks.
Which Rx Drug Plans Show Enrollment Growth, Losses?
2015-05-05 23:05:17| Beverages - Topix.net
Six major prescription drug plans have shown increases in 2015, while four other top plans had declines, according to government data analyzed by Avalere Health, a health care advisory firm. , the largest plan by number of beneficiaries, fell from 3.7 million in 2014 to 3.6 million this year.
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
2015-04-08 13:30:05| Merck.com - Product News
Dateline City: PRINCETON, N.J., and KENILWORTH, N.J. KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). Language: English read more
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »